Brolucizumab

Brolucizumab (also known as RTH258) is a human­ized single-chain antibody fragment that inhibits all isoforms of VEGF-A with a molecular weight of 26 kDa.

“On a molar basis, 6 mg of broluci­zumab equals approximately 12 times the 2.0-mg dose of aflibercept and 22 times the 0.5-mg dose of ranibizumab,” t

 “These attributes may confer potential advantages in the treatment of neovascular AMD. A small molecular weight and high drug concentration gradient between the vitreous and retina may support drug distribution into the retina.

Assuming comparable half-life, higher molar doses of drug may be cleared more slowly from the eye, thus prolonging duration of action,” they explained.

Image result for brolucizumab


reference

Share With Your Friends:

WhatsApp
Telegram
Twitter
LinkedIn

Retina Ward of Farabi Eye Hospital

  • 0
  • 141
  • 174,870
  • 74,088
  • 357
  • 399
  • 2024-02-25